2018
DOI: 10.1016/j.biopha.2018.04.013
|View full text |Cite
|
Sign up to set email alerts
|

The gastric mucosal protective effects of astragaloside IV in mnng-induced GPL rats

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
26
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
8
2

Relationship

2
8

Authors

Journals

citations
Cited by 37 publications
(27 citation statements)
references
References 63 publications
1
26
0
Order By: Relevance
“…In recent years, more scientific researchers have done in-depth research on the treatment of GPL. However, they used the rats treated with MNNG to demonstrate GPL [24, 32, 33]. this method has the limitation that the pathologic degree of the time-consuming and non-uniform digress of pathological degree of the model.…”
Section: Discussionmentioning
confidence: 99%
“…In recent years, more scientific researchers have done in-depth research on the treatment of GPL. However, they used the rats treated with MNNG to demonstrate GPL [24, 32, 33]. this method has the limitation that the pathologic degree of the time-consuming and non-uniform digress of pathological degree of the model.…”
Section: Discussionmentioning
confidence: 99%
“…In conclusion, AS-IV could protect from gastric mucosal injury in this model, partly through regulation of autophagy. Gastric cancer has evolutionary histopathological stages, starting with chronic gastritis, followed by gastric precancerous lesions, including chronic atrophic gastritis, intestinal metaplasia, dysplasia, even carcinoma [59]. However, the role of AS-IV-mediated autophagy and its exact mechanism in gastric precancerous lesions and gastric cancer are still under exploration.…”
Section: Expanding Mechanisms Of Autophagy In Am Extractsmentioning
confidence: 99%
“…Astragaloside IV (AS-IV) is a key active component of the medicinal herb Astragalus membranaceus, which is widely used to treat several diseases including cardiovascular and digestive disorders [15,16]. After AS-IV was administered in rats, pharmacokinetic analysis revealed that the drug was highly accumulated in the liver and kidneys, followed by the heart and lungs [1], implying its plausible protective role in the liver and kidneys.…”
Section: Introductionmentioning
confidence: 99%